New Methods Of Treatment Of Autoimmune Diseases

New Methods Of Treatment Of Autoimmune Diseases.


A late treatment for multiple sclerosis that teaches the body to recognize and then ignore its own nerve tissue appears to be justifiable and well-tolerated in humans, a small new study shows in June 2013. If larger studies verify the technique can slow or stop the disease, the therapy would be a completely unusual way to treat autoimmune diseases such as multiple sclerosis (MS) and type 1 diabetes site here. Most treatments for MS and other autoimmune diseases calling by broadly suppressing immune function, leaving patients unshielded to infections and cancers.



The new treatment targets only the proteins that come under raid when the immune system fails to recognize them as a normal part of the body. By creating endurance to only a select few proteins, researchers hope they will be able to cure the disease but leave the rest of the body's defenses on guard read this. "This is noted work," said Dr Lawrence Steinman, a professor of neurology at Stanford University who was not active with the study.



And "Very few investigators are trying therapies in humans aimed at solely turning off unwanted immune responses and leaving the rest of the immune system solid to fight infections - to do surveillance against cancer. The early results show encouragement". For the study, published in the June 5, 2013 distribution of the journal Science Translational Medicine, researchers in the United States and Germany recruited nine patients with MS.



Seven had the relapsing-remitting conceive of the disease, while two others had unimportant progressive MS (a more advanced phase). All were between the ages of 18 and 55, and were in approving health except for their MS. Blood tests conducted before the treatments showed that each resolute had an immune reaction against at least one of seven myelin proteins.



Myelin is a white conglomeration made of fats and proteins that wraps nerve fibers, allowing them to conduct electrical signals through the body. In MS, the body attacks and step by step destroys these myelin sheaths. The devastation disrupts nerve signals and leads to myriad symptoms, including numbness, tingling, weakness, wastage of balance and disrupted muscle coordination.



Six patients in the study had low disease activity, while three others had a description of more active disease. Most were not experiencing symptoms at the time of their treatment. On the time of the treatments, patients spent about two hours hooked up to a machine that filtered their blood, harvesting silver cells while returning red cells and plasma to the body.



After the oyster-white cells were collected, they were washed and then combined with seven proteins that make up myelin tissue. A chemical was old to link the proteins to the white blood cells, which were dying. In totting up to fighting germs, another important role of the immune system is to get rid of dead and dying tissues.



When these tissues are nonchalant by the spleen, it sends out a signal to the rest of the immune system that the dying tissues are just mild waste. The new treatment aims to take advantage of the body's enervate disposal system. In attaching the myelin proteins to dying white blood cells, the hypothesis is to get the body to also recognize those proteins as harmless and hopefully leave them alone.



In animal models of MS, the same corps of researchers has shown that using this system to induce immune tolerance can stop the progression of disease. This was the earliest test of this kind of therapy in humans, and although the study was too small to show whether the treatment changed the path of the disease, researchers did see some promising signs. Blood tests taken before and after the treatment showed that the infusions turned down safe reactivity to myelin proteins, but didn't affect the immune response to likely infections, like tetanus.



And "We were only trying to turn down the myelin responses, which we did," said research researcher Stephen Miller, a professor of microbiology and immunology at the Northwestern University Feinberg School of Medicine, in Chicago. "And we didn't walk down the response to tetanus. That suggests that this therapy, just love in mice, can induce tolerance in humans".



Patients reported mild and moderate subsidiary effects during their treatments. Nearly all these problems, except for a metallic taste in the mouth, were judged to be uncoordinated to the study treatment. The six patients with mild disease activity showed no new symptoms or worsening in their conditions three months after the infusions. What's more, MRI scans showed no untrained areas of sore after their treatments.



Two of the three patients with more active disease had worsening symptoms within two weeks of treatment. Those symptoms cleared up with steroid treatments. MRI scans showed all three patients developed unexplored lesions that indicated a worsening of inflammation.



None of the patients disoriented neurologic banquet during the six months they were followed after their treatments. "Whether it's going to have a longstanding effect, or an secure in locking down the disease symptoms in MS patients, is going to take a phase 2 or state 3 trial," said Miller, who disclosed that he shares rights to a patent on the technique full report. The con was supported by private grants from foundations in Germany and the United States, and by funding from the German government.

tag : patients disease immune proteins treatment myelin treatments symptoms system

Post a comment

Private comment

Профиль

alejandrafalto

Author:alejandrafalto
Dr. Alejandra Falto

Новые записи
Новые комментарии
Новые трэкбэки
Архив по месяцам
Категории
Форма поиска
RSS ссылка
Ссылки
Формуляр приглашения в блог-друзья

Добавить автора в блог-друзья